Form 4: Cognex VP Sells Shares After Option Exercise
Insider Transaction Report
Cognex Corp's VP and PAO, Laura Ann MacDonald, executed a series of transactions on February 12, 2026, involving the exercise of stock options and subsequent sale of common stock, alongside an additional sale, all under a Rule 10b5-1 trading plan.
Summary
- Laura Ann MacDonald, VP and PAO of Cognex Corp (CGNX), reported changes in her beneficial ownership of common stock.
- On February 12, 2026, MacDonald sold 2,381 shares of common stock at a price of $56.56 per share.
- On the same date, she exercised non-qualified stock options to acquire 12,500 shares of common stock at an exercise price of $38.39 per share.
- Immediately following the option exercise, MacDonald sold 12,500 shares of common stock at an average price of $57.2707 per share.
- All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan.
- Following these transactions, MacDonald directly beneficially owns 2,212 shares of common stock.
- Additionally, 20 shares of common stock are indirectly beneficially owned by her child, for which MacDonald disclaims beneficial ownership except to the extent of her pecuniary interest.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. The transactions are routine insider activity, likely for personal financial planning and diversification, and were executed under a pre-arranged 10b5-1 plan, which mitigates concerns about opportunistic trading.
Positives
- The exercise of stock options indicates a realization of value from previously granted equity compensation.
Negatives
- The net effect of the reported transactions is a reduction in direct beneficial ownership of common stock by 2,381 shares, which could be interpreted as a slight decrease in insider conviction, though often for personal financial planning.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding the company's future performance.
Industry Context
StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common for executives managing their personal portfolios and diversifying holdings. These routine transactions typically do not reflect a change in the company's fundamental outlook or industry trends.
Related Party Transactions
- 20 shares of common stock are indirectly held by the reporting person's child. The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest.
Stakeholder Impact
- Shareholders: Minimal direct impact, as these are routine insider transactions and not indicative of company performance or strategic shifts.
Key Dates
| Date | Description |
|---|---|
| 02/21/2018 | Date exercisable for 12,500 Non-Qualified Stock Options with an exercise price of $38.39. |
| 02/19/2020 | Date exercisable for 30,000 Non-Qualified Stock Options with an exercise price of $51.49. |
| 02/18/2021 | Date exercisable for 42,500 Non-Qualified Stock Options with an exercise price of $50.94. |
| 05/01/2022 | Date exercisable for 10,000 Non-Qualified Stock Options with an exercise price of $48.28. |
| 02/16/2022 | Date exercisable for 13,946 Non-Qualified Stock Options with an exercise price of $90.50. |
| 02/22/2023 | Date exercisable for 23,891 Non-Qualified Stock Options with an exercise price of $64.43. |
| 02/21/2024 | Date exercisable for 30,492 Non-Qualified Stock Options with an exercise price of $47.21 and for 2,754 Restricted Stock Units. |
| 02/20/2025 | Date exercisable for 37,698 Non-Qualified Stock Options with an exercise price of $39.44 and for 5,071 Restricted Stock Units. |
| 03/15/2025 | Date exercisable for 982 Restricted Stock Units. |
| 02/12/2026 | Transaction date for the sale of 2,381 shares, exercise of 12,500 options, and sale of 12,500 shares. |
| 02/18/2026 | Date exercisable for 33,168 Non-Qualified Stock Options with an exercise price of $33.04 and for 12,107 Restricted Stock Units. |
| 02/21/2026 | Expiration date for 2,754 Restricted Stock Units. |
| 02/21/2027 | Expiration date for 12,500 Non-Qualified Stock Options with an exercise price of $38.39 and for 5,071 Restricted Stock Units. |
| 02/20/2027 | Expiration date for 5,071 Restricted Stock Units. |
| 02/18/2028 | Expiration date for 12,107 Restricted Stock Units. |
| 02/20/2028 | Expiration date for 15,000 Non-Qualified Stock Options with an exercise price of $56.44. |
| 02/19/2029 | Expiration date for 30,000 Non-Qualified Stock Options with an exercise price of $51.49. |
| 05/01/2029 | Expiration date for 10,000 Non-Qualified Stock Options with an exercise price of $48.28. |
| 02/18/2030 | Expiration date for 42,500 Non-Qualified Stock Options with an exercise price of $50.94. |
| 02/16/2031 | Expiration date for 13,946 Non-Qualified Stock Options with an exercise price of $90.50. |
| 02/22/2032 | Expiration date for 23,891 Non-Qualified Stock Options with an exercise price of $64.43. |
| 02/21/2033 | Expiration date for 30,492 Non-Qualified Stock Options with an exercise price of $47.21. |
| 02/20/2034 | Expiration date for 37,698 Non-Qualified Stock Options with an exercise price of $39.44. |
| 02/18/2035 | Expiration date for 33,168 Non-Qualified Stock Options with an exercise price of $33.04. |
Keywords
Cognex Corp, CGNX, Insider Trading, Form 4, Stock Options, Common Stock Sale, Rule 10b5-1 Plan, Beneficial Ownership, Laura Ann MacDonald
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.